{"prompt": "['Novartis', 'Confidential', 'Page 47', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '6.4.2 Spirometry', 'The following spirometric assessments will be made:', 'Forced expiratory volume in one second (FEV1)', 'Forced Vital Capacity (FVC)', 'Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity (FEF25-75)', 'Spirometric assessments will be performed per Assessment Schedule Table 6-1 and Timed', 'Assessments Table 6-2.', 'Trough FEV1 for QVM149 150/50/80 g and QVM149 150/50/160 g o.d. delivered via', 'Conceptl is the mean of the two FEV1 values measures at -45 min and -15 min prior to', \"evening dose. Trough FEV1 for the 'free' triple combination of salmeterol/fluticasone 50/500\", 'g b.i.d. delivered as powder via Accuhaler\u00ae + tiotropium 5 g o.d delivered via Respimat\u00ae', 'is the mean of the two FEV1 values measures at -45 min and - 15 min prior to evening dose.', 'Please refer to the Spirometry Guidance in Appendix 2.']['Novartis', 'Confidential', 'Page 48', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '6.4.4 Worsening of asthma', 'Investigators and patients will be instructed how to deal with worsening of asthma symptoms.', 'The data captured in the patient diary and site spirometer will be used to alert the patient', 'and/or investigator to possible signs of worsening asthma. The patient eDiary will instruct the', 'patient to contact the study site if any asthma worsening criteria is met. The investigator will', 'instruct the patient to contact the investigator if at any time during the trial from the run-in', 'onwards one or more of the following criteria of worsening asthma develops:', 'Asthma Worsening Criteria:', '1.', '> 20% decrease in FEV1 from baseline value (this criterion applies to Investigator review', 'at the time of a study visit or via spirometry report)', '2. > 50% increase in SABA use and >8 puffs per day on 2 out of any 3 consecutive days', 'compared to baseline', '3. > 20% decrease in morning (AM) or evening (PM) PEF from baseline on 2 out of any 3', 'consecutive days compared to baseline', '4. < 60% of predicted or personal best PEF compared to baseline', '5. Night time awakenings requiring SABA use on at least 2 out of any 3 consecutive nights']['Novartis', 'Confidential', 'Page 49', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '6. Urgent unscheduled clinic visit due to asthma related deterioration', 'Note: The reference for the worsening of asthma during the run-in period would be the FEV1', 'and PEF taken at Visit 101. The baseline FEV1, and PEF for the treatment period is taken at', 'treatment Day 1 (Visit 201). The baseline for SABA use during the run-in period will be >8', 'puffs and the baseline for the treatment period is taken from the average of the 7 days prior to', 'V201.', 'If any of the above criteria (including the alert from e-diary) are met while a patient is in the', \"run-in or treatment period, the investigator should assess the patient's condition. If this occurs\", 'during run-in period and it is considered a clinically significant asthma worsening in the', \"investigator's opinion, the patient should be treated as appropriate and discontinued prior to\", 'randomization. Once the condition is resolved, if eligibility criteria are met, the patient may', 'be reconsidered for rescreening.', 'If patients develop any of the above criteria during treatment, the patient should notify the', 'investigator and be evaluated by the investigator and treated as clinically appropriate.', 'Worsening of asthma symptoms may require unscheduled evaluation between visits. Study', \"site personnel must be available to monitor and document patient's progress until asthma\", 'control is regained.', '6.4.5 Asthma Exacerbation', 'A severe asthma exacerbation (Draft note for guidance on clinical investigation of medicinal', 'products for treatment of asthma CHMP/EWP/2922/01 Rev.1) is defined as an aggravation of', 'asthma symptoms (like shortness of breath, cough, wheezing, or chest tightness) that requires', 'Systemic Corticosteroid (SCS) for at least three consecutive days and/or a need for an ER', 'visit (or local equivalent structure), hospitalization due to asthma or death due to asthma.', 'Start date and end date:', 'In case of the use of SCSs for at least three days, the first day of treatment will determine', 'the onset date of the event while the last day of treatment will define the stop date.', 'In the event that an ER visit and/or hospitalization due to asthma exacerbation were not', 'associated with a course of SCSs as described above, start and end dates would be defined', 'by the corresponding dates entered by the Investigator in the CRF.', 'A moderate asthma exacerbation in this protocol is defined as the occurrence of two or more', 'of the following:', '1. Progressive increase of at least one of the asthma symptoms like shortness of breath, cough,', \"wheezing, or chest tightness. The symptoms should be outside the patient's usual range of\", 'day-to-day asthma and should last at least two consecutive days.', '2. Increased use of \"rescue\" inhaled bronchodilators defined by:', '>', '50% increase in SABA use and >8 puffs on 2 out of any 3 consecutive days', 'compared to baseline captured', 'Or', 'Night time awakenings requiring SABA use on at least 2 out of any 3 consecutive', 'nights']\n\n###\n\n", "completion": "END"}